CAR T cell therapy efficacy and safety in SLE: A systematic review and pooled analysis of 47 patients across 10 studies
Doi: 10.1007/s00210-025-04425-z
Sayed OA et al. reported that CAR T cell therapy showed promise in refractory SLE, achieving durable remission with manageable toxicity; however further trials are needed to confirm long-term outcomes. Authors consolidated the current evidence on CAR T cell therapy in the treatment of SLE.
This systematic review and pooled analysis of 47 SLE patients treated with CAR T cell therapy demonstrate transformative potential, with most patients achieving remission or LDA state along with serologic normalization. CAR T cell therapy represents a paradigm shift in SLE management, offering deep, drug-free remission in patients with refractory disease. While challenges in relapse, safety, and accessibility persist, its mechanistic superiority over conventional therapies underscores its potential to redefine autoimmune treatment.